Director's Dealing • Dec 6, 2019
Director's Dealing
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information
RNS Number : 1084W
Alliance Pharma PLC
06 December 2019
| For immediate release | 6 December 2019 |
("Alliance" or the "Company")
Grant of Options to Directors
Alliance Pharma plc (AIM: APH), the international specialty pharmaceutical group, announces that the Board has issued options over an aggregate of 540,367 ordinary shares of 1 pence each in the Company, on the recommendation of the Company's Remuneration Committee, to the PDMRs detailed below.
Peter Butterfield, Chief Executive Officer, has been awarded 137,500 unapproved share options under the Company's 2015 Share Option Plan; and, 196,684 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.
Andrew Franklin, Chief Financial Officer, has been awarded 39,011 approved and 55,989 unapproved share options under the Company's 2015 Share Option Plan; and, 111,183 share options have been granted pursuant to the Company's Long-Term Incentive Plan 2019.
The share options awarded under the 2015 Company Share Option Plan have all been granted with an exercise price of 76.9p, being the closing mid-market price on 4th December 2019, and become exercisable on 5th December 2022, being the third anniversary of the date of the grant. The awards granted under the 2019 Long Term Incentive Plan have been granted at nil-cost and also become exercisable on 5th December 2022.
The vesting of these awards is subject to continued employment and the satisfaction of performance conditions based on EPS and TSR targets.
The net effect of the grant of Share Options and the resultant option holdings are shown in the table below:
| Name | Share Options granted | Total no. of options over ordinary shares now held |
| Peter Butterfield | 334,184 | 2,989,184 |
| Andrew Franklin | 206,183 | 1,609,183 |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by person discharging managerial responsibilities.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Mr Peter Butterfield | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Executive Officer - PDMR | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Alliance Pharma plc | |
| b) | Legal Entity Identifier | N/A | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 1.0 pence each ISIN: GB0031030819 |
|
| b) | Nature of the transaction | Grant of Options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Exercise Price (p) | No. of share options |
| 76.9p | 137,500 | ||
| Nil | 196,684 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 137,500 options to acquire shares at £0.769 per share at an aggregate exercise price of £105,737.50. Grant of 196,684 options to acquire shares at nil-cost. |
|
| f) | Date of the transaction | 5 December 2019 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name | Mr Andrew Franklin | |
| 2 | Reason for the notification | ||
| a) | Position/status | Chief Financial Officer - PDMR | |
| b) | Initial notification /Amendment | Initial Notification | |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||
| a) | Name | Alliance Pharma plc | |
| b) | Legal Entity Identifier | N/A | |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code |
Ordinary shares of 1.0 pence each ISIN: GB0031030819 |
|
| b) | Nature of the transaction | Grant of Options | |
| c) | Currency | GBP | |
| d) | Price(s) and volume(s) | Exercise Price (p) | No. of share options |
| 76.9p | 95,000 | ||
| Nil | 111,183 | ||
| e) | Aggregated information - Aggregated volume - Price - Aggregated total |
Grant of 95,000 options to acquire shares at £0.769 per share at an aggregate exercise price of £73,055. Grant of 111,183 options to acquire shares at nil-cost. |
|
| f) | Date of the transaction | 5 December 2019 | |
| g) | Place of the transaction | London Stock Exchange, AIM |
For further information:
Alliance Pharma plc + 44 (0) 1249 466966
Peter Butterfield, Chief Executive Officer
Andrew Franklin, Chief Financial Officer
Buchanan + 44 (0) 20 7466 5000
Mark Court / Sophie Wills / Hannah Ratcliff
Numis Securities Limited + 44 (0) 20 7260 1000
Nominated Adviser: Freddie Barnfield, Huw Jeremy
Corporate Broking: James Black
Investec Bank plc +44 (0) 20 7597 5970
Corporate Finance: Daniel Adams / Ed Thomas
Corporate Broking: Patrick Robb / Tejas Padalkar
Notes to editors:
About Alliance Pharma
Alliance, founded in 1998, is an international specialty pharmaceutical group based in Chippenham, Wiltshire, UK. The Group has sales in more than 100 countries worldwide via direct sales, joint ventures and a wide network of distributors. Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Group continues to explore opportunities to expand its product portfolio.
Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
END
DSHEAKAKEDKNFFF
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.